PARP Inhibitors-induced nausea and vomiting in patients with gynecologic cancer: a prospective, observational, multicenter study.
- Conditions
- Ovarian cancer
- Registration Number
- JPRN-UMIN000039076
- Lead Sponsor
- Gifu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 234
Not provided
1.Patients with a reduction in the initial dose of olaparib and niraparib 2.Patients who need antiemetics at the enrollment. 3.Patients who start taking opioids within 48 hours prior to enrollment 4.Patients with ascites effusion requiring paracentesis 5.Patients with symptomatic brain metastases and cancerous meningitis 6.Patients who have gastrointestinal obstruction 7.Patients who received abdominal or pelvic irradiation within 6 days prior to enrollment 8.Patients who use any drug with antiemetic activity, including NK1RA, 5-HT3RA, corticosteroids, dopamine receptor antagonists, phenothiazine tranquilizers, SSRI, SNRI, SDA, MARTA within 6 days prior to enrollment 9.Other patients who are judged to be inappropriate for the study by the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method